menu
    • menu
    [{"orgOrder":0,"company":"Henlius","sponsor":"Essex Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Henlius","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Henlius \/ Henlius","highestDevelopmentStatusID":"10","companyTruncated":"Henlius \/ Henlius"},{"orgOrder":0,"company":"Henlius","sponsor":"Chiome Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"LIV-2008","moa":"Trop2","graph1":"Oncology","graph2":"Preclinical","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Henlius \/ Henlius","highestDevelopmentStatusID":"4","companyTruncated":"Henlius \/ Henlius"},{"orgOrder":0,"company":"Henlius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Henlius \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Henlius \/ Not Applicable"},{"orgOrder":0,"company":"Henlius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Henlius \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Henlius \/ Not Applicable"},{"orgOrder":0,"company":"Henlius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Henlius \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Henlius \/ Not Applicable"},{"orgOrder":0,"company":"Henlius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Henlius \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Henlius \/ Not Applicable"},{"orgOrder":0,"company":"Henlius","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Henlius","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Henlius \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Henlius \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Henlius","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Serplulimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Henlius \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Henlius \/ Intas Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Henlius

    Menu

    Henlius

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serplulimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Henlius, Intas Get CHMP Nod for HETRONIFLY® in Small Cell Lung Cancer

                            Details : Hetronifly (serplulimab) is a PD-1 inhibitor antibody, which is currently being evaluated for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer.

                            Brand Name : Hetronifly

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 21, 2024

                            Lead Product(s) : Serplulimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serplulimab,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : $195.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Henlius Deepens Collaboration with Intas to Bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

                            Details : Under the terms of the agreement, Henlius will be responsible for clinical development, manufacturing and supply upon launch of specific formulation of HANSIZHUANG (serplulimab injection), Henlius' novel anti-PD-1 mAb.

                            Brand Name : Hansizhuang

                            Molecule Type : Large molecule

                            Upfront Cash : $44.4 million

                            October 27, 2023

                            Lead Product(s) : Serplulimab,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : $195.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serplulimab,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

                            Details : Hansizhuang (serplulimab) is a novel humanized monoclonal anti-PD-1 antibody, which is approved for the first-line treatment of extensive stage small cell lung cancer in combination with carboplatin and etoposide.

                            Brand Name : Hansizhuang

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 17, 2023

                            Lead Product(s) : Serplulimab,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serplulimab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HANBEITAI in Patients with Adv...

                            Details : Results from both groups (group A, n=20; group B, n=21) demonstrated that Hansizhuang (serplulimab) plus HLX04 was safe and well-tolerated. As assessed by IRRC, the ORR was 30.0% (95% CI, 11.9–54.3) in group A and 14.3% (95% CI, 3.0–36.3) in group B.

                            Brand Name : Hansizhuang

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 09, 2022

                            Lead Product(s) : Serplulimab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serplulimab,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of S...

                            Details : The study results demonstrated that HLX10 (serplulimab) in combination with chemotherapy can significantly extend median OS to 15.4 months when compared to control group in first-line SCLC, gaining global recognition while leapfrogging immunotherapy trea...

                            Brand Name : HLX10

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 06, 2022

                            Lead Product(s) : Serplulimab,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serplulimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Henlius will Release 4 Oral Presentations of 2 Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab a...

                            Details : Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb serplulimab and the bevacizumab biosimilar HLX04 used in patients with advanced hepatocellular carcinoma. Serplulimab injection is anti-PD-1 mAb for treatmen...

                            Brand Name : HLX10

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 18, 2021

                            Lead Product(s) : Serplulimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LIV-2008

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Chiome Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Henlius Has Reached an Exclusive License Agreement with Chiome for Antibodies Targeting Human TROP2

                            Details : Chiome agreed to grant Henlius an exclusive right and license to antibodies targeting human TROP2 and related intellectual property rights to research, develop, manufacture and commercialize the Licensed Products in China.

                            Brand Name : LIV-2008

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 14, 2021

                            Lead Product(s) : LIV-2008

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Chiome Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Henlius

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Essex Biotechnology

                            Deal Size : $25.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Essex and Henlius Ink Global Co-Development and License Agreement to Jointly Develop Bevacizumab for Treatment...

                            Details : Pursuant to the Agreement, Essex and Henlius will co-develop the bevacizumab HLX04 for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD).

                            Brand Name : HLX04

                            Molecule Type : Large molecule

                            Upfront Cash : $10.0 million

                            October 15, 2020

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Essex Biotechnology

                            Deal Size : $25.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth